Home
NewsNewsFairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
In a significant move for the reproductive medicine industry, Fairfax Cryobank and IVI RMA North America have officially announced a strategic partnership designed to Fairfax IVI expand donor sperm access. This collaboration seeks to provide individuals and couples with high-quality donor sperm, significant savings, and premium support services as they pursue their family-building goals.
Through this new alliance, IVI RMA North America patients will gain direct access to Fairfax Cryobank’s extensive nationwide network of diverse donors. Beyond increasing the availability of donor sperm, the partnership introduces various programmes aimed at enhancing financial accessibility and overall value for patients. Key benefits include personalised guidance, genetic compatibility insights, and flexible programme options tailored to the unique needs of each family.
To ensure a seamless experience, Fairfax Cryobank will manage the shipping and secure storage of samples while providing dedicated support throughout the process. The integration of these services into IVI RMA’s clinical framework is intended to reduce the logistical and emotional complexities often associated with fertility treatments.
Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, highlighted the importance of this collaboration for patient care: “This partnership with Fairfax Cryobank is an important advancement in our mission to expand access to high-quality, patient-centred fertility care to all Americans. By combining IVI RMA's clinical expertise with Fairfax Cryobank's high-quality diverse donor sperm and value-added services, we are reducing the financial and emotional barriers to reproductive treatment and empowering more individuals and families to pursue parenthood with greater confidence and clarity.”
The partnership will see Fairfax Cryobank’s donor selection process fully integrated into the personalised fertility treatment plans at IVI RMA’s 27 North American laboratories. This streamlined approach includes coordinated lab services and genetic counselling, allowing patients to make more informed clinical decisions. Furthermore, both organisations have reaffirmed their commitment to inclusive services, supporting LGBTQ+ families, single moms by choice, and any individuals requiring donor sperm to build their families. Dr. Harvey Stern, MD, PhD, Medical Director of Fairfax Cryobank, expressed his pride in the joint effort:
“We are proud to partner with IVI RMA North America to deliver a seamless patient-centred experience for those building their families. By combining our extensive donor network, secure storage, and personalised guidance with IVI RMA's clinical leadership and advanced IVF laboratories, we are ensuring patients receive trusted support at every step of their journey.”
Fairfax Cryobank, established in 1986, is renowned for its comprehensive donor screening and testing procedures, operating seven locations across the United States to serve recipients globally. IVI RMA North America, which includes Reproductive Medicine Associates, Boston IVF, and TRIO, has facilitated the birth of over 220,000 babies to date. As part of IVI RMA Global, the network remains a leader in evidence-based fertility solutions, employing over 6,000 people across 15 countries.
The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.
Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.
La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.
IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.
Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.
Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.
The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.
